10-Q · May 6, 2026
TScan Therapeutics reported disappointing Q1 2026 results, with a significant decline in revenue to $1 million from $2.2 million a year earlier, largely attributed to decreased collaboration revenues. While the company…
Earnings analysis · 10-Q
TCRX earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
TScan's Q2 2026 revenue of $1.051 million improved 7% sequentially but fell approximately 65% year over year, and diluted EPS weakened modestly sequentially to negative $0.23. The net loss improved to $30.4 million, but…
Read full summary
TScan's Q2 2026 revenue of $1.051 million improved 7% sequentially but fell approximately 65% year over year, and diluted EPS weakened modestly sequentially to negative $0.23. The net loss improved to $30.4 million, but the company remains heavily cash consuming, has only $100.2 million of cash expected to fund operations into Q2 2027, and has newly disclosed substantial doubt about continuing as a going concern. No updated quantitative revenue or EPS guidance was provided, and the unavailable $20.0 million debt tranche increases financing risk.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.23
- Gross margin
- 100.0%
What stood out
-
Sequential Revenue Recovery, Large YoY Decline
Q2 2026 revenue was $1.051 million, up approximately 7% from $0.982 million in Q1 2026 but down approximately 65% from $3.0 million in Q2 2025.
-
EPS Improved Year Over Year
Diluted EPS was negative $0.23 versus negative $0.22 in Q1 2026 and negative $0.28 in Q2 2025, representing a $0.01 sequential deterioration but a $0.05 year-over-year improvement.
-
Lower Net Loss
Net loss narrowed to $30.4 million in Q2 2026 from $37.0 million in the comparable prior-year period; the six-month net loss was $59.0 million.
-
Cash Funds Operations Into Q2 2027
Management reported $100.2 million of cash and cash equivalents as of June 30, 2026, which it believes will fund the current operating plan into Q2 2027.
-
Existing Debt Facility Defined
The company had $32.5 million fully funded under its SVB term loan, while the additional $20.0 million tranche was not drawn by June 30, 2026 and is no longer available.
-
Controls Remained Effective
Management stated that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026, and reported no material change in internal control over financial reporting.
What to watch
-
New Going-Concern Risk
The company newly identifies substantial doubt about its ability to continue as a going concern for at least twelve months following the filing. Although cash was $100.2 million at June 30, 2026, management expects funding only into Q2 2027 and states that additional capital is required.
-
Debt Capacity Reduced
The $20.0 million second tranche under the SVB facility was not drawn before June 30, 2026 and is no longer available, leaving the company with the $32.5 million funded tranche and increasing reliance on future financing.
-
New AI Compliance and Cyber Risk
The filing adds a material AI-specific risk, noting potential cybersecurity, data privacy, regulatory, intellectual property and operational impacts. The EU Artificial Intelligence Act may impose high-risk obligations with certain requirements deferred to 2027 and 2028.
-
Revenue Model Remains Collaboration-Dependent
Revenue declined approximately 65% year over year to $1.051 million in Q2 2026 from $3.0 million in Q2 2025, while the company has never generated revenue from product sales and does not expect significant product revenue until regulatory approval and commercialization.
-
Persistent Losses and Accumulated Deficit
The company reported net losses of $30.4 million for the three months and $59.0 million for the six months ended June 30, 2026, and an accumulated deficit of $563.9 million as of June 30, 2026.
Management's outlook
The 10-Q does not provide or reaffirm quantitative revenue or EPS guidance. The prior 2026 revenue outlook was $12 million, while management states that $100.2 million of cash and cash equivalents is expected to fund the current operating plan into Q2 2027.
Earlier filings 4
10-K · March 4, 2026
TScan Therapeutics reported a challenging year with continued net losses driven primarily by high operating expenses in research and development. Their revenue grew to $10.3 million in 2025 from $2.8 million in 2024,…
10-Q · November 12, 2025
TScan Therapeutics (TCRX) reported Q3 2025 results with revenues reaching $2.51 million, surpassing the prior year figure of $1.05 million, driven by a collaboration agreement with Amgen. Despite this revenue growth,…
10-Q · August 12, 2025
In Q2 2025, TScan Therapeutics reported substantial revenue growth, achieving $3.1 million compared to just $0.5 million in Q2 2024, driven primarily by a collaboration with Amgen. However, the company continued to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.